AZNAstraZenecaRunning, no new patients
Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC
Papillary Renal Cell Carcinoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 148 (final count)
- Started
- Oct 28, 2021
- Main results expected
- Dec 31, 2025
- Fully finished
- Feb 1, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-Free Survival (PFS) /savolitinib plus durvalumab relative to sunitinib
Measured over: Approximately 28 months post first subject randomized
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05043090 · record last updated 2026-10-21 · checked 2026-11-09 15:47 UTC